CV Dynamics to resubmit Omnicarbon PMA to FDA within a few months.
This article was originally published in The Gray Sheet
CV DYNAMICS OMNICARBON CARDIAC VALVE PMA RESUBMISSION will come within the next few months, the company estimates. CV Dynamics plans to submit a revised version of a premarket approval application for the heart valve that was rejected by the agency in 1989. The company plans to supplement the filing with information including updated clinical data and comprehensive fatigue data on the Omnicarbon's pyrolite housing.
You may also be interested in...
MedicalCV aims to capture 1-2% of the roughly $360 mil. worldwide mechanical heart valve market over the next year after gaining FDA approval of its Omnicarbon pyrolite ceramic-based heart valve on July 26.
No device-related warning letters were released by the US FDA the week of 26 January.